The 2022 San Antonio Breast Cancer Symposium (SABCS) was held from December 6 to 10 in San Antonio, Texas. In this podcast, Norah Lynn Henry, MD, PhD, FASCO, discusses research in treating metastatic breast cancer and preventing breast cancer from developing or recurring.
-
Updates on new medications being studied for treating hormone receptor-positive, HER2-negative metastatic breast cancer, including new selective estrogen receptor downregulator (SERD) drugs, a type of hormonal therapy that blocks the ability of estrogen to attach to estrogen receptors. [2:26]
-
Results from 2 studies looking at the order in which medications used to treat HER2-positive metastatic breast cancer are given and comparing the targeted therapy drugs trastuzumab deruxtecan (Enhertu) and trastuzumab emtansine (Kadcyla) in treating people with this type of cancer. [3:20]
-
Findings from a study evaluating whether using a low dose of the hormonal therapy drug tamoxifen helped reduce the risk of breast cancer developing in people at high risk for the disease and helped reduce side effects from the treatment. [4:28]
-
Results from the POSITIVE clinical trial, which was studying whether pausing hormonal therapy so people with hormone receptor-positive breast cancer could become pregnant increased their risk of recurrence. [5:43]
Dr. Henry is a professor and interim chief of the University of Michigan's Division of Hematology/Oncology in the Department of Internal Medicine. She is also the breast oncology disease lead at the Rogel Cancer Center. Dr. Henry specializes in the care of patients with all stages of breast cancer. She is the 2023 Cancer.Net Associate Editor for Breast Cancer.
Disclosure information for Dr. Henry can be found in her individual biography linked to in the paragraph above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.